Brigatinib vs Ensartinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Brigatinib

Marketed by Takeda Pharmaceutical Company

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02737501 · Phase 3 · completed

This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT04223596 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months (missed)

Result source: NCT03596866

Ensartinib · Ensacove

Marketed by Xcovery Holdings and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02767804 · Phase 3 · active, not recruiting

This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.

Next expected readout: February 2027 · NCT05241028 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)

Result source: NCT02767804

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBrigatinibEnsartinib
PFS, median24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461
—Trial running · NCT06955325
OS, median25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461
—Trial running · NCT06955325
ORR74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
—Trial running · NCT06955325
Duration of response, median33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573
—Trial running · NCT06955325

PFS, median

Brigatinib
24.0 vs 11.1vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
10 other results
  • 19.3 vs 19.2 n 125 · Phase 3 · primary NCT03596866
  • 16.8 vs 16.6 n 125 · Phase 3 · secondary NCT03596866
  • 9.2 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 15.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 12.6 90 mg QD · n 15 · Phase 1/2 · secondary NCT01449461
  • 11 90 mg QD-180 mg QD · n 21 · Phase 1/2 · secondary NCT01449461
  • 5.4 180 mg QD/90 mg BID · n 40 · Phase 1/2 · secondary NCT01449461
  • 5.4 240 mg QD/120 mg BID/300 mg QD · n 7 · Phase 1/2 · secondary NCT01449461
  • 5.4 120 mg QD/60 mg BID · n 17 · Phase 1/2 · secondary NCT01449461
  • 1.8 30 mg QD/60 mg QD · n 5 · Phase 1/2 · secondary NCT01449461
Ensartinib
—Trial running · NCT06955325

OS, median

Brigatinib
25.9b90 mg · n 112NCT02094573
8 other results
  • 40.6 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 21.3 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
  • 11.6 90 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 17.9 90 mg QD-180 mg QD · n 17 · Phase 1/2 · secondary NCT01449461
  • 8.3 240 mg QD/120 mg BID/300 mg QD · n 11 · Phase 1/2 · secondary NCT01449461
  • 7.3 180 mg QD/90 mg BID · n 25 · Phase 1/2 · secondary NCT01449461
  • 7.3 120 mg QD/60 mg BID · n 12 · Phase 1/2 · secondary NCT01449461
  • 5.3 30 mg QD/60 mg QD · n 6 · Phase 1/2 · secondary NCT01449461
Ensartinib
—Trial running · NCT06955325

ORR

Brigatinib
74.5% vs 62.3%vs Crizotinib90 mg QD/180 QD · n 137NCT02737501
6 other results
  • 45.5% 90 mg · n 112 · Phase 2 · primary NCT02094573
  • 57.3% 90 mg - 180 mg · n 110 · Phase 2 · primary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · primary NCT03535740
  • 51.8% 90 mg · n 112 · Phase 2 · secondary NCT02094573
  • 56.4% 90 mg - 180 mg · n 110 · Phase 2 · secondary NCT02094573
  • 26.2% 90 mg/180 mg With Optional Dose Escalation to 240 mg · n 103 · Phase 2 · secondary NCT03535740
Ensartinib
—Trial running · NCT06955325

Duration of response, median

Brigatinib
33.1 vs 13.8vs Crizotinib90 mg QD/180 QD · n 102NCT02737501
2 other results
  • 12 90 mg · n 51 · Phase 2 · secondary NCT02094573
  • 13.8 90 mg - 180 mg · n 63 · Phase 2 · secondary NCT02094573
Ensartinib
—Trial running · NCT06955325
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Brigatinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBrigatinibEnsartinib
Dropout rate
85.4%90 mg QD/180 QDa
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
97.6%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone90 mg
NCT02094573 · Phase 2
n/a: no completion milestone90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
0%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
0%225 mg
NCT01625234 · Phase 1/2
0%250 mg
NCT01625234 · Phase 1/2
0%200 mg
NCT01625234 · Phase 1/2
0%100 mg
NCT01625234 · Phase 1/2
0%50 mg
NCT01625234 · Phase 1/2
0%25 mg
NCT01625234 · Phase 1/2
n/a: no completion milestone200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—90 mg QD/180 QDa
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
—
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
3.6%90 mg
NCT02094573 · Phase 2
12.7%90 mg - 180 mg
NCT02094573 · Phase 2
—90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
—240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
3.8%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
16.7%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
9.4%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
26.7%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
8.3%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
11.1%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
0%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
—225 mgb
NCT01625234 · Phase 1/2
show 7 more results
—225 mg
NCT01625234 · Phase 1/2
—250 mg
NCT01625234 · Phase 1/2
—200 mg
NCT01625234 · Phase 1/2
—100 mg
NCT01625234 · Phase 1/2
—50 mg
NCT01625234 · Phase 1/2
—25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Serious AEs
41.2%90 mg QD/180 QDa
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
30.4%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
53.2%90 mg
NCT02094573 · Phase 2
62.7%90 mg - 180 mg
NCT02094573 · Phase 2
46.6%90/180 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
23.1%240 mg
NCT03535740 · Phase 2 · registry result, not featured evidence
35.6%90 mg/180 mg
NCT03410108 · Phase 2 · registry result, not featured evidence
55.6%90 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
43.8%90 mg QD-180 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
73.3%240 mg QD/120 mg BID/300 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
62.5%180 mg QD/90 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
55.6%120 mg QD/60 mg BID
NCT01449461 · Phase 1/2 · registry result, not featured evidence
16.7%30 mg QD/60 mg QD
NCT01449461 · Phase 1/2 · registry result, not featured evidence
50%225 mgb
NCT01625234 · Phase 1/2
show 7 more results
43.6%225 mg
NCT01625234 · Phase 1/2
50%250 mg
NCT01625234 · Phase 1/2
54.5%200 mg
NCT01625234 · Phase 1/2
40%100 mg
NCT01625234 · Phase 1/2
33.3%50 mg
NCT01625234 · Phase 1/2
25%25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
90 mg QD/180 QDa
diarrhoea 57.4%
blood creatine phosphokinase increased 50%
cough 36%
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 12 more results
blood creatine phosphokinase increased 73.6%
aspartate aminotransferase increased 56.8%
alanine aminotransferase increased 47.2%
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
90 mg
nausea 43.1%
vomiting 40.4%
headache 35.8%
NCT02094573 · Phase 2
90 mg - 180 mg
nausea 50%
diarrhoea 46.4%
cough 40.9%
NCT02094573 · Phase 2
90/180 mg
diarrhoea 39.8%
blood creatine phosphokinase increased 34%
nausea 28.2%
NCT03535740 · Phase 2 · registry result, not featured evidence
240 mg
diarrhoea 53.8%
blood creatine phosphokinase increased 38.5%
aspartate aminotransferase increased 23.1%
NCT03535740 · Phase 2 · registry result, not featured evidence
90 mg/180 mg
blood creatine phosphokinase increased 77.9%
hypertension 47.1%
diarrhoea 45.2%
NCT03410108 · Phase 2 · registry result, not featured evidence
90 mg QD
fatigue 50%
diarrhoea 44.4%
headache 44.4%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
90 mg QD-180 mg QD
diarrhoea 53.1%
fatigue 50%
nausea 50%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
240 mg QD/120 mg BID/300 mg QD
fatigue 80%
cough 53.3%
diarrhoea 53.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
180 mg QD/90 mg BID
nausea 68.8%
diarrhoea 43.8%
fatigue 39.6%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
120 mg QD/60 mg BID
fatigue 50%
nausea 50%
aspartate aminotransferase increased 38.9%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
30 mg QD/60 mg QD
abdominal pain 50%
nausea 50%
electrocardiogram qt prolonged 33.3%
NCT01449461 · Phase 1/2 · registry result, not featured evidence
225 mgb
gastrointestinal disorders 25%
nausea 25%
vomiting 25%
NCT01625234 · Phase 1/2
show 7 more results
225 mg
gastrointestinal disorders 60.6%
nausea 38.3%
vomiting 25.5%
NCT01625234 · Phase 1/2
250 mg
gastrointestinal disorders 50%
vomiting 50%
nausea 30%
NCT01625234 · Phase 1/2
200 mg
gastrointestinal disorders 54.5%
nausea 45.5%
vomiting 36.4%
NCT01625234 · Phase 1/2
100 mg
gastrointestinal disorders 40%
anaemia 20%
blood and lymphatic 20%
NCT01625234 · Phase 1/2
50 mg
gastrointestinal disorders 33.3%
nausea 33.3%
vomiting 33.3%
NCT01625234 · Phase 1/2
25 mg
anaemia 25%
blood and lymphatic 25%
blood creatinine increased 25%
NCT01625234 · Phase 1/2
200 mg
hypoalbuminaemia 100%
anaemia 50%
arthralgia 50%
NCT02898116 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 11 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Brigatinib

PFS 24.016 vs 11.072 Crizotinib months90 mg QD/180 QD
time to event · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 2 more results
19.253 vs 19.187 Alectinib months
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
16.789 vs 16.591 Alectinib months
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 74.5% (n=137) vs 62.3% (n=138) Crizotinib90 mg QD/180 QD
responder rate · % of participants
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Intracranial ORR 66% (n=47) vs 14.3% (n=49) Crizotinib90 mg QD/180 QD
responder rate · % of participants
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 1 more result
73.3% (n=30) vs 67.7% (n=31) Alectinib
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Intracranial PFS 23.951 vs 5.52 Crizotinib months90 mg QD/180 QD
absolute value · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Crizotinib months90 mg QD/180 QD
time to event · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs NA Alectinib months
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response 33.15 vs 13.832 Crizotinib months90 mg QD/180 QD
time to event · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Time to Response 1.84 vs 1.873 Crizotinib months90 mg QD/180 QD
time to event · months
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
Disease Control 85.4% (n=137) vs 86.2% (n=138) Crizotinib90 mg QD/180 QD
responder rate · % of participants
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
EORTC QLQ-C30 GHS 4.007 vs -4.088 Crizotinib score @ 144wk90 mg QD/180 QD
absolute change · score
NCT02737501 · Phase 3 · monotherapy · Advanced Solid Tumors, Non-Small Cell Lung Cancer · phase 3
ORR 52% (n=125) vs 61% (n=123) Alectinib
responder rate · % of participants
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Duration of Response 17.544 vs 20.205 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Response 1.873 vs 1.84 Alectinib months
time to event · months
BIRC Assessed
NCT03596866 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

+ 20 further endpoints in the CSV export.

Ensartinib

ORR 42% (n=81) @ 78wk225 mg
event count · % of participants
No placebo or comparator arm
NCT01625234 · Phase 1/2 · converted to % from 34 participants as posted
Stable Disease 0% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
SD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Progressive Disease 100% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
PD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brigatinib's landscape · Ensartinib's landscape